Kyungpook National University Industry-academic Cooperation Foundation

Etnova Therapeutics Corp.

Other

Yong Min Chang

Tae-Jeong Kim

Yeoun Hee Kim

Sha Joung Chang

Md Kamrul Islam

So Yeon Kim

Hee Kyeong Kim

Tae Jeong Kim

Hee-Kyung Kim

Sung-Wook Gu

Hee Kyung Kim

Seonguk Jin

Seungtae Woo

Sung Bo Kyung

Ga Ram Choi

Jung Jin Lee

The present invention relates to a gadolinium-based compound of a Chemical Formula 1, a method for producing the same, and an MRI contrast agent containing the same. [Chemical Formula 1] [structural formula] In chemical formula 1, A and Linker represent linking groups, and RB represents a Rose Bengal-derived part.

Gadolinium-based compound, method for producing same, and MRI contrast agent containing same

The present invention relates to a compound of formula 1 and a pharmaceutical composition containing same. This compound may be useful as: a therapeutic agent for degenerative brain diseases including dementia or cranial nerve diseases and developmental disorders caused by neural cell damage, various degenerative neural diseases, ischemic nerve diseases, or neural damage diseases; a learning ability-improving agent; and a cognitive function-improving agent. [Formula 1] in formula 1 above, B represents a part derived from retinoic acid.

Compound and pharmaceutical composition containing same for treating or preventing neural damage, neural disease, or developmental disorder through promoting proliferation, differentiation, and/or regeneration of neural cells

The present invention relates to a novel gadolinium-based compound having a structure in which a gadolinium complex and ferulic acid are linked via a linker, a preparation method therefor, and an MRI contrast agent containing same.

Gadolinium-based compound, preparation method therefor, and MRI contrast agent containing same

Disclosed is a compound, a complex comprising same, an anti-cancer pharmaceutical composition, and an anti-cancer drug. The compound can have the structure represented by chemical formula 1.

Compound having novel structure, complex comprising same, anti-cancer pharmaceutical composition, and anti-cancer drug

A compound is disclosed that can be used as an anti-inflammatory agent, a cyclooxygenase-2 inhibitor, a therapeutic agent for brain diseases, or a MRI contrast medium. The compound can have the structure represented by chemical formula 1.

Compound, antiinflammatory drug comprising the compound and cyclooxygenase-2 inhibitor comprising the compound

Disclosed are a gadolinium complex with a high relaxibity at a high magnetic field, a method for synthesizing the complex, and an MRI contrast agent containing the gadolinium complex. The gadolinium complex may be expressed as a Chemical Formula 1: 

Gadolinium complex, method for synthesis of the gadolinium complex, and MRI contrast agent including the gadolinium complex

The present disclosure relates to a magnetic resonance imaging (MRI) contrast agent containing a gadolinium complex, and more specically, to a DO3A-tranexamic acid compound having a structure of a chemical formula 1, or an ester compound thereof, and gadolinium complexes thereof. The DO3A-tranexamic acid compound or the ester compound thereof may be used to prepare gadolinium complexes. The gadolinium complexes exhibit thermodynamic and kinetic stabilities, and show the relaxation rate equal to that of the clinical contrast agent which is currently commercially available. Therefore, the gadolinium complexes can be widely used as an MRI contrast agent.

Gadolinium complex comprising DO3A-tranexamic acid conjugate

The present invention relates to a magnetic resonance imaging (MRI) contrast agent including a gadolinium complex, more particularly to a DO3A-tranexamic acid or its ester compound, which is represented by the Chemical Formula 1. A DO3A-tranexamic acid or its ester compound may be prepared according to the present invention and a gadolinium complex may be prepared using the compound. An MRI contrast agent including the gadolinium complex prepared according to the present invention as an active ingredient has higher relaxivity as compared to the currently commercially available contrast agent. In addition, the MRI contrast agent according to the present invention has bifunctionality of liver-specific and blood-pool contrasting effect. Accordingly, since the MRI contrast agent including the gadolinium complex according to the present invention satisfies the key properties required for a contrast agent for MRI, it can be widely used as an MRI contrast agent and can provide enhanced contrasting effect as compared to the existing contrast agent.

MRI contrast agent having gadolinium complex

The present invention relates to a paramagnetic polynuclear metal complex having enhanced self-relaxation rate and thermodynamic stability, and more particularly, to a synthetic method of a novel DTPA-bis-amide-histidine ligand and DTPA-bis-amide-aspartic acid ligand, a novel gadolinium complex ([Gd(L)HO]) using the ligand, and a paramagnetic polynuclear metal complex using the gadolinium complex. The paramagnetic polynuclear metal complex is able to fix three or more metals (one gadolinium and two metal ions), thereby providing more excellent self-relaxation rate than the commercially available contrast agents. Thus, it can be widely applied to an MRI contrast agent because of meeting the high self-relaxation rate required as a contrast agent of magnetic resonance imaging (MRI).

Growing community of inventors

Daegu, South Korea

Yong Min Chang